Header Logo

Xueqing Hu

TitleFellow,Postdoctoral Research
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentStephenson Cancer Center
AddressSOCC
800 NE 10th St
Oklahoma City OK 73104
Phone405/761-3622
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hu X, Khatri U, Shen T, Wu J. Progress and challenges in RET-targeted cancer therapy. Front Med. 2023 May 03. PMID: 37131086.
      Citations:    Fields:    
    2. Khatri U, Dayal N, Hu X, Larocque E, Naganna N, Shen T, Liu X, Holtsberg FW, Aman MJ, Sintim HO, Wu J. Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors. Mol Cancer Ther. 2023 Apr 17; OF1-OF9. PMID: 37070927.
      Citations:    Fields:    
    3. Hu X, Liu X, Khatri U, Wu J. The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases. Drug Resist Updat. 2023 May; 68:100958. PMID: 36990046.
      Citations:    Fields:    Translation:HumansCells
    4. Shen T, Hu X, Liu X, Subbiah V, Mooers BHM, Wu J. The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib. NPJ Precis Oncol. 2021 Jun 07; 5(1):48. PMID: 34099825.
      Citations: 12     
    5. Liu X, Hu X, Shen T, Li Q, Mooers BHM, Wu J. RET kinase alterations in targeted cancer therapy. Cancer Drug Resist. 2020; 3(3):472-481. PMID: 35582449.
      Citations: 3     
    Hu's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (9)
    Explore
    _
    Co-Authors (4)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _